DHFR2 and head and neck squamous cell carcinoma: Methotrexate (MTX), an inhibitor of 1-C metabolism enzyme dihydrofolate reductase (DHFR/DHFRL1) is FDA-approved for the palliative care of HNSCC patients and often investigated in combination with other treatments to improve therapeutic efficacy (25).